Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | HRH4 | Q9H3N8 | 4/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
| ▸ | CDC25B | P30305 | 1/20 | 0.39 |
| ▸ | F10 | P00742 | 1/20 | 0.38 |
| ▸ | DRD1 | P21728 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | BCHE | P06276 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5606199 | 1.00 | TMEM97 (0.48) | TMEM97SIGMAR1LMNACA2TAAR1 | |
| SCHEMBL2182755 | 1.00 | TMEM97 (0.48) | TMEM97SIGMAR1LMNACA2TAAR1 | |
| SCHEMBL3508958 | 0.93 | TMEM97 (0.45) | TMEM97SIGMAR1LMNACA2TAAR1 | |
| SCHEMBL25305166 | 0.92 | TMEM97 (0.44) | TMEM97SIGMAR1LMNACA2TAAR1 | |
| SCHEMBL25303747 | 0.92 | TMEM97 (0.44) | TMEM97SIGMAR1LMNACA2TAAR1 | |
| SCHEMBL24207804 | 0.92 | TMEM97 (0.44) | TMEM97SIGMAR1LMNACA2TAAR1 | |
| SCHEMBL12882864 | 0.88 | TMEM97 (0.42) | TMEM97SIGMAR1LMNACA2TAAR1 | |
| SCHEMBL26510718 | 0.87 | CA2 (0.43) | TMEM97SIGMAR1LMNACA2TSHR | |
| SCHEMBL11932962 | 0.86 | CA1 (0.45) | TMEM97SIGMAR1CA2TSHR | |
| SCHEMBL14317554 | 0.86 | CA1 (0.45) | TMEM97SIGMAR1CA2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 143 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108409782-B | Synthetic method of alkynyl-modified phospholipid derivative for preparing functional phospholipid giant vesicle | 咸阳师范学院 | 2020-05-15 | — | — | CN | claimed |
| CN-108409782-A | A kind of synthetic method for the alkynyl-modified phospholipid derivative being used to prepare functional phosphatide Giant Vesicles | 咸阳师范学院 | 2018-08-17 | — | — | CN | claimed |
| JP-6157506-A | — | — | None | — | — | JP | disclosed |
| CN-122055141-A | Polyvinylpyrrolidone stabilizer, composition, use and preparation method thereof | 环球生命科学解决方案加拿大有限公司 | 2026-05-15 | — | — | CN | disclosed |
| US-12595336-B2 | Method for producing maleimide polyethylene glycol derivative | NOF CORPORATION (JP) | 2026-04-07 | — | — | US | disclosed |
| US-12453785-B2 | Macrocyclic chelators and methods of use thereof | JANSSEN BIOTECH, INC. (US) | 2025-10-28 | — | — | US | disclosed |
| EP-4265667-B1 | METHOD FOR PRODUCING MALEIMIDE POLYETHYLENE GLYCOL DERIVATIVE | NOF CORP (JP) | 2025-07-23 | — | — | EP | disclosed |
| US-20250114305-A1 | LIPIDIC COMPOUNDS, AND USES THEREOF | SANOFI (FR) | 2025-04-10 | — | — | US | disclosed |
| WO-2025056466-A1 | POLYVINYLPYRROLIDONE STABILIZING AGENTS, COMPOSITIONS, USES, AND MANUFACTURING METHODS THEREOF | GLOBAL LIFE SCIENCES SOLUTIONS CANADA ULC (CA) | 2025-03-20 | — | — | WO | disclosed |
| WO-2025056467-A1 | POLYPHOSPHOESTER STABILIZING AGENTS, COMPOSITIONS, USES, AND MANUFACTURING METHODS THEREOF | GLOBAL LIFE SCIENCES SOLUTIONS CANADA ULC (CA) | 2025-03-20 | — | — | WO | disclosed |
| EP-4466248-A1 | LIPIDIC COMPOUNDS, AND USES THEREOF | Sanofi (FR) | 2024-11-27 | — | — | EP | disclosed |
| US-6143908-A | Process for preparation of 1,3-dioxolane-4-methanol compounds | DAISO CO., LTD. (JP) | 2000-11-07 | — | — | US | disclosed |
| US-6124479-A | Process for the preparation of 1,3-dioxolane-4-methanols | DAISO CO., LTD. (JP) | 2000-09-26 | — | — | US | disclosed |
| EP-0930311-A1 | PROCESS FOR PREPARING 1,3-DIOXOLANE-4-METHANOL COMPOUNDS | DAISO CO., LTD. (JP) | 1999-07-21 | — | — | EP | disclosed |
| EP-0926147-A1 | PROCESS FOR PREPARING 1,3-DIOXOLANE-4-METHANOL COMPOUNDS | DAISO CO., LTD. (JP) | 1999-06-30 | — | — | EP | disclosed |
| US-5795561-A | TUMOR SPECIFIC; MEDICAL DIAGNOSIS | THE BOARD OF REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 1998-08-18 | — | — | US | disclosed |
| US-5347030-A | Radioiodinated phospholipid ether analogues and methods of using same | THE BOARD OF REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 1994-09-13 | — | — | US | disclosed |
| JP-H06157506-A | PRODUCTION OF ISOPROPYLIDENEBENZYLGLYCEROL | NIPPON OIL & FATS CO LTD | 1994-06-03 | — | — | JP | disclosed |
| EP-0191724-A2 | 1,4-Dihydropyridine derivatives, their preparation and pharmaceutical compositions containing them | SANDOZ AG (CH) | 1986-08-20 | — | — | EP | disclosed |
| US-4423071-A | ANOXIA, ANTICONVULSANTS, GLYCERYL BIS-(DI-N-PROPYLACETATES) | SANOFI (FR) | 1983-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12595336-B2 | Method for producing maleimide polyethylene glycol derivative | F12, C9, H1-0 | TMEM97 2643/4885SIGMAR1 675/4885LMNA 468/4885 |
| US-20250114305-A1 | LIPIDIC COMPOUNDS, AND USES THEREOF | NR1H2, NR1H3, LPAR3 | TMEM97 856/4885SIGMAR1 40/4885LMNA 555/4885 |
| US-12453785-B2 | Macrocyclic chelators and methods of use thereof | CLASP1, CLTC, CD47 | TMEM97 2144/4885SIGMAR1 4517/4885LMNA 4231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.